Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 6/20 | 0.58 |
| ▸ | CES1 | P23141 | 6/20 | 0.58 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1912788 | 1.00 | CES2 (0.58) | CES2CES1EGFRPTGS2ALDH1A1 | |
| SCHEMBL13729327 | 0.83 | CES2 (0.53) | CES2CES1EGFRALDH1A1LMNA | |
| SCHEMBL2989494 | 0.79 | CES2 (0.65) | CES2CES1PTGS2ALDH1A1LMNA | |
| SCHEMBL6969664 | 0.79 | EGFR (0.45) | CES2CES1EGFRALDH1A1LMNA | |
| SCHEMBL1772976 | 0.76 | ALDH1A1 (0.45) | CES2CES1ALDH1A1TDP1KMT2A | |
| SCHEMBL2354896 | 0.74 | CES2 (0.72) | CES2CES1PTGS2ALDH1A1LMNA | |
| SCHEMBL7219046 | 0.74 | CES1 (1.00) | CES2CES1PTGS2ALDH1A1LMNA | |
| SCHEMBL10497754 | 0.74 | CES2 (0.67) | CES2CES1EGFRLMNAL3MBTL1 | |
| Valerophenone SCHEMBL5615151 | 0.74 | L3MBTL1 (0.72) | CES2CES1PTGS2LMNARAB9A | |
| Valerophenone SCHEMBL9725402 | 0.74 | L3MBTL1 (0.72) | CES2CES1PTGS2LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-20070208048-A1 | New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-09-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-20040116424-A1 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208048-A1 | New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators | C3AR1, C5AR1, C5AR2 | CES2 4777/4885CES1 3590/4885EGFR 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.